Adil el Housseini | Cellular Neuroscience | Best Researcher Award

Published on by Neuroscientists

Mr. Adil el Housseini | Cellular Neuroscience | Best Researcher Award

Mr. Adil el Housseini | Ibn Zohr University Agadir Morocco | Morocco

Adil EL Housseini is a dedicated PhD candidate in biology at Ibn Zohr University, Faculty of Sciences of Agadir, specializing in toxicology, biochemistry, and the molecular characterization of scorpion venoms. His doctoral research explores the biochemical composition, ecotoxicity, and pathophysiological mechanisms of venoms from selected Buthid species, with a particular focus on developing novel therapeutic strategies for scorpion envenomation. Adil has contributed to the scientific community through peer-reviewed publications and authored book chapters spanning biomedical polymers, chitosan-based therapeutic applications, radioprotective biomaterials, and neurobiological insights into astrocyte function. His work on the kinetics of brain oxidative stress following scorpion envenomation highlights his strong command of experimental toxicology and neurobiochemical analysis. With an h-index of 1, two indexed documents, and two citations, he continues to build a research profile grounded in rigorous experimentation and interdisciplinary scientific inquiry. Adil’s skills include venom biochemistry, laboratory toxicology, data interpretation, and scientific writing, supported by strong language proficiency in Arabic, French, and English. His commitment to advancing knowledge in venom toxicology and biomedical sciences positions him as a promising emerging researcher contributing to both fundamental understanding and applied therapeutic innovation.

Profile: Google Scholar | Orcid

Featured Publications

Ait Hamdan, Y., Rhazi, M., El-Mansoury, B., Kabdy, H., Oukhrib, M., Ait Baba, A., … (2024). Astrocytes functions and their involvement in brain injury: A focus on the biomaterials’ role in mitigating traumatic brain injury. In Physiology and Function of Glial Cells in Health and Disease (pp. 145–163).

Mabsor-Zgandaoui, S., Rachmoune, K., Aftais, I., Elamrani, F. E., Amradi, I., … (2026). Biomedical polymers: Foundations and future innovations in medicine. In Biomedical Applications and Toxicity of Polymers, Nanoparticles

Ait Hamdan, Y., Armadi, I., Elamrani, F. E., Mekouar, M., El Housseini, A., … (2026). Therapeutic implications of chitosan and its derivatives: Focus on cancer treatment. In Biomedical Applications and Toxicity of Polymers, Nanoparticles

Rachmoune, K., Mabsor-Zgandaoui, S., El Housseini, A., Ait Hamdan, Y., … (2026). Radioprotective effects of chitosan polysaccharides and biomedical applications. In Biomedical Applications and Toxicity of Polymers, Nanoparticles

Armadi, I., Elouali, S., Abana, A., El Housseini, A., Loqman, S., & Belbachir, A. (2025). Overview of biomaterials classification, properties, and biomedical applications. In Innovations and Applications of Advanced Biomaterials in Healthcare 

lavanya Choppavarapu | Molecular and Cellular Neuroscience | Research Excellence Award

Published on by Neuroscientists

Dr. lavanya Choppavarapu | Molecular and Cellular Neuroscience | Research Excellence Award

Dr. lavanya Choppavarapu | Medical college of Wisconsin | United States

Lavanya Choppavarapu, Ph.D., is a research scientist specializing in cancer genomics, chromatin biology, and genome-editing technologies. She currently serves at the Medical College of Wisconsin, where she leads projects applying CRISPR-Cas9 approaches to investigate mechanisms of endocrine-resistant breast cancer. Her postdoctoral training at the Medical College of Wisconsin and the University of Texas Health Science Center San Antonio strengthened her expertise in regulatory genomics, particularly in defining the roles of chromatin looping, 3D genome organization, and enhancer–promoter interactions across breast, prostate, and pancreatic cancer models. Earlier, at the National Institute of Mental Health and Neurosciences, she contributed extensively to human genetics research as a Senior and Junior Research Fellow, and further gained foundational experience at the All India Institute of Medical Sciences. Her academic background spans biotechnology and human genetics, providing a multidisciplinary foundation for her cancer-focused investigations. Dr. Choppavarapu has produced impactful scientific contributions, reflected in 189 citations, an h-index of 8, an i10-index of 7, and 132 citation counts with an h-index of 6 and i10-index of 5 across platforms. Her work continues to advance understanding of gene regulation, epigenetic control, and chromatin dynamics in cancer progression.

Profile: Google Scholar

Featured Publications

Lavanya, C., Venkataswamy, M. M., Sibin, M. K., Srinivas Bharath, M. M., Manoj, M. J., & others. (2018). Down regulation of human telomerase reverse transcriptase (hTERT) expression by BIBR1532 in human glioblastoma LN18 cells. Cytotechnology, 70(4), 1143–1154.

Sibin, M. K., Bhat, D. I., Narasingarao, K. V. L., Lavanya, C., & Chetan, G. K. (2015). CDKN2A (p16) mRNA decreased expression is a marker of poor prognosis in malignant high-grade glioma. Tumor Biology, 36(10), 7607–7614.

Li, J., Fang, K., Choppavarapu, L., Yang, K., Yini, X., & others. (2021). Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistance. Clinical Epigenetics, 13, Article 175.

Yang, Y., Choppavarapu, L., Fang, K., Naeini, A. S., Nosirov, B., Li, J., Yang, K., & others. (2020). The 3D genomic landscape of differential response to EGFR/HER2 inhibition in endocrine-resistant breast cancer cells. Biochimica et Biophysica Acta (BBA) – Gene Regulatory Mechanisms, 1863(11), 194631.

Lavanya, C., Sibin, M. K., Srinivas Bharath, M. M., Manoj, M. J., & others. (2016). RNA interference mediated downregulation of human telomerase reverse transcriptase (hTERT) in LN18 cells. Cytotechnology, 68(6), 2311–2321.

Sibin, M. K., Bhat, D. I., Lavanya, C., Manoj, M. J., Aakershita, S., & Chetan, G. K. (2014). CDKN2A exon-wise deletion status and novel somatic mutations in Indian glioma patients. Tumor Biology, 35(2), 1467–1472.